Prognostic impact of angiopoietin-2 in multiple myeloma

No abstract is available for this paper.

• Publication year

  2014

• Venue

  Journal of Cancer Research and Clinical Oncology

• Publication date

  2014-06-08

• Fields of study

  Medicine

• Identifiers
  DOI 10.1007/s00432-014-1731-2PMID 24906877PMCID PMC11823498
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Serum levels of angiopoietin-2 are associated with the growth of multiple myeloma

  2013cited by this paper
• Emerging roles of endoglin/CD105 and angiogenic cytokines for disease development and progression in multiple myeloma patients

  2013cited by this paper
• Angiopoietins as biomarker of disease activity and response to therapy in multiple myeloma

  2013cited by this paper
• Synergistic effect of vascular endothelial growth factor and angiopoietin-2 on progression free survival in multiple myeloma.

  2013cited by this paper
• Circulating angiopoietin‐1 to angiopoietin‐2 ratio is an independent prognostic factor for survival in newly diagnosed patients with multiple myeloma who received therapy with novel antimyeloma agents

  2012cited by this paper
• Clinical significance of sCD105 in angiogenesis and disease activity in multiple myeloma.

  2012cited by this paper
• Role of platelet‐derived growth factor‐AB in tumour growth and angiogenesis in relation with other angiogenic cytokines in multiple myeloma

  2012cited by this paper
• Normalization of the serum angiopoietin-1 to angiopoietin-2 ratio reflects response in refractory/resistant multiple myeloma patients treated with bortezomib

  2008cited by this paper
• Angiogenesis and antiangiogenic therapy in hematologic malignancies.

  2007cited by this paper
• Differential levels of soluble angiopoietin‐2 and Tie‐2 in patients with haematological malignancies

  2006cited by this paper
• The role of the bone microenvironment in the pathophysiology and therapeutic management of multiple myeloma: interplay of growth factors, their receptors and stromal interactions.

  2006cited by this paper
• Molecular classification of multiple myeloma: a distinct transcriptional profile characterizes patients expressing CCND1 and negative for 14q32 translocations.

  2005cited by this paper
• The Tie-2 ligand Angiopoietin-2 destabilizes quiescent endothelium through an internal autocrine loop mechanism

  2005cited by this paper
• The Role of the Angiopoietins in Tumour Angiogenesis

  2004cited by this paper
• Expressions of vascular endothelial growth factor and angiopoietin-2 in myeloma cells.

  2003cited by this paper
• Proangiogenic properties of human myeloma cells: production of angiopoietin-1 and its potential relationship to myeloma-induced angiogenesis.

  2003cited by this paper
• CD105 is important for angiogenesis: evidence and potential applications

  2003cited by this paper
• Mechanisms of normal and tumor-derived angiogenesis.

  2002cited by this paper
• Complementary actions of VEGF and Angiopoietin‐1 on blood vessel growth and leakage *

  2002cited by this paper
• Angiopoietin and Tie signaling pathways in vascular development.

  2001cited by this paper
• Bone marrow microvessel density is a prognostic factor for survival in patients with multiple myeloma

  2000cited by this paper
• Vascular-specific growth factors and blood vessel formation

  2000cited by this paper
• New model of tumor angiogenesis: dynamic balance between vessel regression and growth mediated by angiopoietins and VEGF

  1999cited by this paper
• Angiopoietin-2, a natural antagonist for Tie2 that disrupts in vivo angiogenesis.

  1997cited by this paper
• Angiogenic factors.

  1987cited by this paper

• Associations of ANGPT2 expression and its variants (rs1868554 and rs7825407) with multiple myeloma risk and outcome

  2025influential citation
• Small Fish, Big Answers: Zebrafish and the Molecular Drivers of Metastasis

  2025cites this paper
• Evaluation of angiopoietin-2 level in patients with multiple myeloma at presentation and in remission state

  2023cites this paper
• Ang2-Targeted Combination Therapy for Cancer Treatment

  2022cites this paper
• The Role of Marrow Microenvironment in the Growth and Development of Malignant Plasma Cells in Multiple Myeloma

  2021cites this paper
• Endothelial activation and stress index (EASIX) is a reliable predictor for overall survival in patients with multiple myeloma

  2020cites this paper
• High levels of FLT3-ligand in bone marrow and peripheral blood of patients with advanced multiple myeloma

  2017cites this paper
• Bone marrow micro-environment is a crucial player for myelomagenesis and disease progression

  2017cites this paper
• Therapeutic targeting of the angiopoietin–TIE pathway

  2017cites this paper
• Microvessel Density as a Surrogate Prognostic Marker in Patients with Multiple Myeloma: A Meta-Analysis

  2017cites this paper
• Elevated Angiopoietin-2 Level in Patients With Continuous-Flow Left Ventricular Assist Devices Leads to Altered Angiogenesis and Is Associated With Higher Nonsurgical Bleeding

  2016cites this paper
• Interrelationship between angiogenesis, inflammation and oxidative stress in Indian patients with multiple myeloma

  2016cites this paper
• Potential role of FLT3-ligand in the angiogenic process of multiple myeloma.

  2015cites this paper